Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Welcome to The MDS Sessions brought to you by the Video Journal of Hematological Oncology (VJHemOnc). This exclusive session features roundtable discussions from the 1st International Workshop on Myelodysplastic Syndromes (iwMDS) 2022 with leading experts in the field. Our experts discuss several topics, including immune dysregulation and targeting in MDS, clonal hematopoiesis and pre-MDS states, updates in classification and risk stratification, and more.
In this session chaired by Uwe Platzbecker, MD, Leipzig University Hospital, Leipzig, Germany, Alan List, MD, Precision BioSciences, Durham, NC, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, and Daniel Starczynowski, PhD, Cincinnati Children’s Hospital, Cincinnati, OH, discuss innate immune dysregulation and targeting in MDS, covering topics such as IRAK inhibition and NLRP3 and CD47 targeting, and sharing their thoughts on the future of MDS therapy.
In this discussion chaired by Hetty Carraway, MD, Cleveland Clinic, Cleveland, OH, Justin Taylor, MD, Sylvester Comprehensive Cancer Center, Miami, FL, Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, and Olatoyosi Odenike, MD, UChicago Medicine, Chicago, IL, share some insights into improving the efficiency of drug approval in MDS. Topics covered include the challenges of treating patients with TP53 mutation and high-risk disease, the biology behind XPO1 inhibition, and an overview of the MDS MyeloMATCH efforts.
In this roundtable discussion chaired by Amer Zeidan, MBBS, Yale School of Medicine, New Haven, CT, Rena Buckstein, MD, FRCPC, Sunnybrook Health Sciences Centre, Toronto, Canada, and Valeria Santini, MD, University of Florence, Florence, Italy, discuss key highlights from the iwMDS 2022 meeting, commenting on key presentations and take-home messages, as well as the importance of improving clinical trial design and access to therapeutic agents for patients with MDS.
iwMDS 2022 has been supported by: